Kura Oncology (NASDAQ:KURA) Shares Cross Above 50-Day Moving Average – Should You Sell?

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $10.28 and traded as high as $10.57. Kura Oncology shares last traded at $10.39, with a volume of 1,137,954 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have commented on KURA. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a report on Monday, June 15th. Lake Street Capital started coverage on shares of Kura Oncology in a report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Citizens Jmp reiterated a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $25.46.

Kura Oncology Stock Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The stock has a 50 day simple moving average of $10.28 and a two-hundred day simple moving average of $9.28. The company has a market cap of $922.32 million, a PE ratio of -3.10 and a beta of 0.35.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. The business had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. Equities analysts predict that Kura Oncology, Inc. will post -3.45 EPS for the current year.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider directly owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently made changes to their positions in KURA. State Street Corp raised its stake in Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after acquiring an additional 1,587,959 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after purchasing an additional 1,121,228 shares during the period. Renaissance Technologies LLC raised its stake in shares of Kura Oncology by 111.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after purchasing an additional 965,256 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after purchasing an additional 820,020 shares during the period. Finally, Qube Research & Technologies Ltd grew its position in Kura Oncology by 63.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after buying an additional 738,761 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.